期刊的一位编辑委员会成员提交了一个未经请求的审查文章。编辑表示，该期刊将考虑这篇文章，但怀疑这篇文章已被委托或甚至由毒品公司撰写。他/批定提交人必须在可以接受这篇文章之前提供金融披露声明。该期刊发表了审查条，这些条款被两个独立审稿人归因。他的竞争利益披露的作者，他一直是销售该药物的公司的付费顾问。出版后几个月，药物公司的代理商订购了这篇文章的重印。该代理要求措辞：“此文献审查由[x]支持”被包含在每个重印的封面上。该代理商被告知，由于提交人没有披露，因此无法增加此声明。代理人坚持，所以期刊联系了作者。提交人问：“最后一篇文章是否有这些词语或某种东西，这些词或某种东西指出了[x]的部分支持？” A copy of the agent’s wording and the competing interest statement from the published article were sent to the author, who replied that he was fine with it as long as the publisher was. The author was then asked to explain the extent of the drug company’s involvement in writing the review article. The author replied that the competing interest statement in the article was accurate; the review had been written independently of any pharmaceutical company, and that the requested statement from the agent was inappropriate. The author was contacted again to point out the contradiction in his two replies. At the same time the agent was asked to question the drug company as to whether it had paid the author to write the review, and to confirm the extent to which the drug company had been involved in preparation of the manuscript. The agent did not reply; neither did the drug company. Eventually, the agent cancelled the reprint order. The author finally replied to confirm that he had been confused by the original request, thinking that clarification of whether he was a paid consultant to the drug company was required. He said that when it became apparent in a follow-up email that the drug company wanted the extra statement added, he realised it was inappropriate. The author assured the editors that the drug company would write a letter of explanation soon. The letter has yet to arrive.
一篇有七名贡献者的论文被提交，但没有通信作者。唯一能证明是谁发出了这份文件的是一封来自一家公关公司的电子邮件。在与编辑部取得联系后，公关公司证实，该报将考虑出版。然后联系署名的投稿人，询问他们是否同意将他们的名字附在论文上，询问通讯作者是谁，以及他们是否希望声明任何利益冲突。这引起了一场非常有趣的骚动。一名作者说，这篇论文是他和其他投稿作者应邀参加的一次研讨会的结果。他自己认为，他只是向有关制药公司提供建议，并为此收取了一定费用。他认为是一个误会导致公关公司把报纸送去审查，但他并不知道他们这么做了，并建议把报纸撕碎。另一位作者打来电话说，他几乎不记得了，肯定也没见过最终的文件。第三位作者打来电话时有些苦恼，他担心自己可能会被指控有某种形式的不当行为，从未想过他的参与会导致一篇论文被提交给一家杂志。 The most interesting letter of all was from the first named author who had subsequently written an editorial for the journal that was fairly critical of the drug concerned. The PR company who was acting for the drug company, she said, had submitted the paper on her behalf without her knowledge. Guidelines about the drug had also been published, with which she was not happy, but she had eventually signed an agreement to let her name be used in connection with these. The company told her that she was the only person among all those attending the seminar who had refused to do so, and as such, was creating unnecessary difficulties. The same company had previously published another article to which they had put her name, but which she had not written. This author feels very abused, particularly as she wrote to the PR company requesting that they did not use her name again. The intriguing finale to the story is that a Royal College had been negotiating with the PR company to represent it. On hearing of this incident, the College decided to make other arrangements.
编辑们遇到了他的杂志主编给一封信给审查员的一封信，该评论者被声称他建议接受稿件。事实上，他建议口头和书面形象。有问题的论文是对相对普遍的医疗状况的治疗选择的指导方针。作者声称他们的结论和治疗性建议是“证实”，并推荐了一种新的昂贵的药物作为一线治疗。稿件的评论被混合了。一位审阅者只提出了一些评论和推荐的出版物。第二次审稿人对表观偏见的关注表示关切，并怀疑有制药公司参与纸质的写作。在科学编辑定期审查稿件时，编辑建议拒绝稿件，这是在手稿中写下的“日志”。主编决定从指引专家那里要求第三次审查。bob官方app与此同时，主要提交人与主编的长度谈过。 Although the expert reviewer expressed concerns about the manuscript, the editor-in-chief chose to accept the manuscript for publication. In accordance with journal policy, the reviewers were notified that the manuscript had been accepted, prompting the second reviewer to again express concern about bias. The editor-in-chief replied, saying that the editor had recommended publication. Under the previous editor-in-chief, there had been a formal policy with the professional body with which the journal was associated, outlining the journal’s editorial freedom. But after he left this began to change. A memo was sent from the association stipulating that any editorial material published in the journal from the association should have an elected official as the author, even if a researcher on staff or a scientific committee had written it.The editor questioned this policy on the basis that it was at odds with the definition of authorship by the International Committee of Medical Journal Editors (ICMJE).The editor-in-chief ignored these concerns. Shortly thereafter, the association’s CEO announced that no letters should be published in the association’s journal that criticised association policy. The editor-in-chief initially stated to the journal staff that he disagreed with this and requested that any such letters be directed to him. He assured staff that if he thought these letters merited publication, he would discuss them with the CEO. Since then, no letter criticising association policy has been published. When a scientific editor submits an article to his own journal, the policy was that another scientific editor would handle the manuscript; likewise, the fate of the manuscript would be made known to the author/editor in a confidential manner. The editor had co-authored a manuscript with another researcher and had submitted it to the journal for consideration. Several months later, in a meeting of copy editors and publication staff to discuss the placement of accepted manuscripts, the editor-in-chief announced that the reviewers had recommended rejection. He had not informed the editor beforehand. In actual fact, none of the original reviewers had recommended rejecting the paper. Manuscripts that had not been accepted were not usually discussed at these meetings and such behaviour contravened the ICMJE recommendations. The editor-in-chief said he would request another opinion before he made the final decision. When the co-author of the paper wrote, asking when the final decision would be taken, the editor in chief accused the editor of breaching confidentiality but wrote to the co-author assuring him that the manuscript would be treated fairly and promptly. The editor did not send out the manuscript for another opinion for almost two weeks.When he did, he identified in the covering letter that “he would elect to reject the manuscript” but sought the reviewer’s opinion. However, two days earlier, he had sent a letter to one of the original reviewers asking him to write a “single or several papers” on the exact same topic. About two weeks later, the editor-in-chief rejected our manuscript, apologising for the delay, and noting “we had some difficulty finding a person to give an editorial opinion of the review.” In a further instance, the editor was asked to review a manuscript for the journal that purported to be an evidence-based guideline. The other reviewers included the previous editor of the journal and an outside reviewer. The editor identified several concerns and included suggestions on how the manuscript could be strengthened; the previous editor gave very similar feedback. The third reviewer had only a few superficial comments, such as a title change. However, the editor-in-chief requested an additional review from an expert in evidence-based medicine, but accepted the manuscript with minor revisions, including the title change, before receiving these comments. Later, the additional review came in, seriously questioning the evidence base of the manuscript, but it was never sent to the author. The manuscript was published with minor revisions. The editor was sacked. The staff were told only that confidentiality precluded giving an explanation; unofficially it was intimated that he had simply been too difficult to get along with. The journal is still publishing, and the relationship between the Association and the Journal is increasingly intimate. There appears to have been a Faustian bargain made between the CEO of the Association and the editor-in-chief of the Journal whereby, in exchange for compromising editorial freedom in sensitive areas for the Association, he could publish what he wanted without feeling constrained by the usual editorial standards. _ If feedback from peer review is ignored, who will know? Most journal editors work in relative isolation and there is virtually no quality control. _ Who polices the relationship between a science-based association and its journal, a relationship that has its own particular set of challenges, involving both scientific and political elements. _ What can be done to stop/prevent corruption within the editorial office of a scientific publication, an issue that has virtually escaped discussion and consideration within the scientific community? _ What will it take to create the political will to ensure the integrity of scientific editors? _ There is often no way to formally investigate and address alleged abuses of editorial power, especially if these abuses are in the interests of the publisher or parent organisation.